Abvc Biopharma (ABVC) Receivables (2012 - 2024)
Abvc Biopharma's (ABVC) quarterly Receivables came in at $1.2 million in Q3 2024, up 92.66% YoY from $625903.0 in Q4 2023, and down 15.31% on a QoQ basis from $1.4 million in Q2 2024.
Abvc Biopharma (ABVC) Receivables (2012 - 2024) Analysis & Trends
Abvc Biopharma (ABVC) has 9 years of Receivables data on file, last reported at $1.2 million in Q3 2024.
- Quarterly Receivables rose 92.66% year-over-year to $1.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.2 million (up 92.66% YoY) and the FY2023 annual result came in at $1.6 million, up 4.81% from the prior year.
- Receivables fell to $1.2 million in Q3 2024, from $1.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.4 million in Q2 2024 to a low of $4083.0 in Q1 2024.
- A 5-year average of $645036.9 and a median of $538574.0 in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables jumped 1212.72% — and 2024, when it tumbled 99.37%.
- Tracing ABVC's Receivables over 5 years: stood at $303147.0 in 2020, then slipped by 7.41% to $280692.0 in 2021, then soared by 352.87% to $1.3 million in 2022, then plunged by 33.71% to $842650.0 in 2023, then soared by 43.11% to $1.2 million in 2024.
- The last three Receivables figures came in at $1.2 million (Q3 2024), $1.4 million (Q2 2024), and $4083.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Abvc Biopharma | 22.94 Mn | 22.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 4,083.00 |
| Dec 31, 2023 | 842,650.00 |
| Sep 30, 2023 | 625,903.00 |
| Jun 30, 2023 | 538,574.00 |
| Mar 31, 2023 | 644,117.00 |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 47,680.00 |
| Jun 30, 2022 | 431,699.00 |
| Mar 31, 2022 | 426,596.00 |
| Dec 31, 2021 | 280,692.00 |
| Sep 30, 2021 | 473,193.00 |
| Jun 30, 2021 | 442,499.00 |
| Mar 31, 2021 | 1.10 Mn |
| Dec 31, 2020 | 303,147.00 |
| Sep 30, 2020 | 779,232.00 |
| Jun 30, 2020 | 971,232.00 |
| Mar 31, 2020 | 447,995.00 |
| Dec 31, 2019 | 306,844.00 |